FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133874396> ?p ?o ?g. }

• W2133874396 endingPage "886" @default.
• W2133874396 startingPage "878" @default.
• W2133874396 abstract "Objectives:Dabigatran etexilate is a new oral direct thrombin inhibitor for prophylaxis of venous thromboembolism (VTE) in patients who have elective surgery for total hip replacement (THR) or total knee replacement (TKR). Among the advantages of dabigatran etexilate over subcutaneous prophylaxis with Low Molecular Weight Heparin (LMWH) are reduced resource uses for (i) teaching patients to self-inject; (ii) home-care visits for subcutaneous administration; and (iii) absence of heparin-induced thrombocytopenia (HIT). Based on the demonstrated non-inferiority, the aim of this study was to conduct a cost-minimization analysis of oral dabigatran etexilate vs subcutaneous low-molecular weight heparin (LMWH) and fondaparinux from the Dutch healthcare perspective.Methods:A retrospective cohort study was conducted to measure resource use associated with subcutaneous prophylaxis. Results of this study were used in the model to elucidate specific advantages of dabigatran etexilate, next to reduced needs for self-inject teaching and lack of Heparin-Induced Thrombocytopenia. Drug and other resource utilization data were combined with local unit costs. Probabilistic sensitivity analysis was performed to account for uncertainty around relevant parameters included.Results:Home-care visits for subcutaneous administration problems were needed in 9.9% (95% CI = 6.4–13.4) and 9.6% (95% CI = 5.8–13.4) of THR and TKR patients, respectively. Based on costs for 1000 patients treated with dabigatran etexilate vs LMWHs, per patient cost-savings with dabigatran etexilate were estimated at €30.68 (95% CI = 2.01–65.52) and €23.19 (95% CI = 0.69–48.48) for THR and TKR, respectively. The probability that dabigatran etexilate would be cost-saving was estimated at 98.3% and 97.9% for THR and TKR, respectively. These cost-savings were even higher when including fondaparinux in the analysis, with per patient cost-savings of €69.87 (43.42–106.10) and €18.33 (1.63–41.26) for THR and TKR, respectively. Separate calculations for dabigatran etexilate vs nadroparin and dalteparin in THR resulted in probabilities of achieving cost-savings with dabigatran etexilate of 36.2% and 100%, respectively. For TKR these probabilities were estimated at 54.3% and 100%, respectively.Conclusions:Thromboprophylaxis with dabigatran etexilate is cost-saving in patients undergoing THR and TKR from the Dutch healthcare perspective, compared to subcutaneous LMWHs." @default.
• W2133874396 created "2016-06-24" @default.
• W2133874396 creator A5026143441 @default.
• W2133874396 creator A5035040485 @default.
• W2133874396 creator A5070794861 @default.
• W2133874396 creator A5085746174 @default.
• W2133874396 date "2012-06-07" @default.
• W2133874396 modified "2023-09-25" @default.
• W2133874396 title "Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands" @default.
• W2133874396 cites W108910897 @default.
• W2133874396 cites W1795001500 @default.
• W2133874396 cites W1967628526 @default.
• W2133874396 cites W1996053109 @default.
• W2133874396 cites W2000438765 @default.
• W2133874396 cites W2022932023 @default.
• W2133874396 cites W2024455472 @default.
• W2133874396 cites W2053310485 @default.
• W2133874396 cites W2067751006 @default.
• W2133874396 cites W2072115658 @default.
• W2133874396 cites W2087462313 @default.
• W2133874396 cites W2105079657 @default.
• W2133874396 cites W2115348966 @default.
• W2133874396 cites W2127663207 @default.
• W2133874396 cites W2132071353 @default.
• W2133874396 cites W2140704109 @default.
• W2133874396 cites W2170524066 @default.
• W2133874396 doi "https://doi.org/10.3111/13696998.2012.691144" @default.
• W2133874396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22563715" @default.
• W2133874396 hasPublicationYear "2012" @default.
• W2133874396 type Work @default.
• W2133874396 sameAs 2133874396 @default.
• W2133874396 citedByCount "11" @default.
• W2133874396 countsByYear W21338743962014 @default.
• W2133874396 countsByYear W21338743962016 @default.
• W2133874396 countsByYear W21338743962018 @default.
• W2133874396 countsByYear W21338743962020 @default.
• W2133874396 countsByYear W21338743962022 @default.
• W2133874396 crossrefType "journal-article" @default.
• W2133874396 hasAuthorship W2133874396A5026143441 @default.
• W2133874396 hasAuthorship W2133874396A5035040485 @default.
• W2133874396 hasAuthorship W2133874396A5070794861 @default.
• W2133874396 hasAuthorship W2133874396A5085746174 @default.
• W2133874396 hasBestOaLocation W21338743961 @default.
• W2133874396 hasConcept C126322002 @default.
• W2133874396 hasConcept C141071460 @default.
• W2133874396 hasConcept C194828623 @default.
• W2133874396 hasConcept C2776301958 @default.
• W2133874396 hasConcept C2776710957 @default.
• W2133874396 hasConcept C2776877702 @default.
• W2133874396 hasConcept C2776884760 @default.
• W2133874396 hasConcept C2777557582 @default.
• W2133874396 hasConcept C2778104916 @default.
• W2133874396 hasConcept C2778336525 @default.
• W2133874396 hasConcept C2778810321 @default.
• W2133874396 hasConcept C2779161974 @default.
• W2133874396 hasConcept C2780868729 @default.
• W2133874396 hasConcept C2991741193 @default.
• W2133874396 hasConcept C42219234 @default.
• W2133874396 hasConcept C71924100 @default.
• W2133874396 hasConceptScore W2133874396C126322002 @default.
• W2133874396 hasConceptScore W2133874396C141071460 @default.
• W2133874396 hasConceptScore W2133874396C194828623 @default.
• W2133874396 hasConceptScore W2133874396C2776301958 @default.
• W2133874396 hasConceptScore W2133874396C2776710957 @default.
• W2133874396 hasConceptScore W2133874396C2776877702 @default.
• W2133874396 hasConceptScore W2133874396C2776884760 @default.
• W2133874396 hasConceptScore W2133874396C2777557582 @default.
• W2133874396 hasConceptScore W2133874396C2778104916 @default.
• W2133874396 hasConceptScore W2133874396C2778336525 @default.
• W2133874396 hasConceptScore W2133874396C2778810321 @default.
• W2133874396 hasConceptScore W2133874396C2779161974 @default.
• W2133874396 hasConceptScore W2133874396C2780868729 @default.
• W2133874396 hasConceptScore W2133874396C2991741193 @default.
• W2133874396 hasConceptScore W2133874396C42219234 @default.
• W2133874396 hasConceptScore W2133874396C71924100 @default.
• W2133874396 hasIssue "5" @default.
• W2133874396 hasLocation W21338743961 @default.
• W2133874396 hasLocation W21338743962 @default.
• W2133874396 hasLocation W21338743963 @default.
• W2133874396 hasOpenAccess W2133874396 @default.
• W2133874396 hasPrimaryLocation W21338743961 @default.
• W2133874396 hasRelatedWork W1493835275 @default.
• W2133874396 hasRelatedWork W187639498 @default.
• W2133874396 hasRelatedWork W1977323500 @default.
• W2133874396 hasRelatedWork W1989240554 @default.
• W2133874396 hasRelatedWork W2061130726 @default.
• W2133874396 hasRelatedWork W2077527033 @default.
• W2133874396 hasRelatedWork W2133874396 @default.
• W2133874396 hasRelatedWork W2164615189 @default.
• W2133874396 hasRelatedWork W2993800134 @default.
• W2133874396 hasRelatedWork W2470806244 @default.
• W2133874396 hasVolume "15" @default.
• W2133874396 isParatext "false" @default.
• W2133874396 isRetracted "false" @default.
• W2133874396 magId "2133874396" @default.
• W2133874396 workType "article" @default.